Advancing the Treatment Paradigm for mCRPC: Insights into Combination Therapy and Future Directions : Episode 4
Opinion
Video
The Safety Profile of RAD-ENZ
Author(s):
Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy being crucial considerations, particularly given the potential impact on future treatment options.
Video Player is loading.
Video content above is prompted by the following:
- Can you discuss the safety profile of the combination of RAD-ENZ?
- Keeping the safety profile of RAD-ENZ in mind, do you have any concerns about implementing the PEACE 3 protocol and introducing radium treatment as you are thinking about the possible need for future therapies?
Related Videos
Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
Navigating Access Barriers: Resources to Support New Treatment Access
Overcoming Challenges in Accessing New Therapies for NMIBC
Selecting Between Receptor Pathway Inhibitors for mHSPC
The Use of Ultra-Low PSA in Specific Patient Profiles
The MOA of TLX250
The importance of studying efficacy and safety of treatment in Black patients with mHSPC
The ZIRCON Trial
Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions
Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
Related Content
